SELENOP

Across TCGA pan-cancer cohorts, SELENOP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SELENOP data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SELENOP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SELENOP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where SELENOP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.384	0.849	.003	55	view →
CCRCC	DFS	Median	III,IV	0.903	0.530	.002	46	view →
PDAC	DFS	Median	All	0.478	0.331	.011	4	view →
HNSC	OS	Median	All	0.957	1.000	.017	2	view →
LSCC	DFS	Median	II,III,IV	0.870	0.963	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SELENOP–LUAD (OS)

Open the LUAD breakdown →